{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:28:11Z","timestamp":1790015291859,"version":"4.0.1"},"reference-count":267,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07470-7","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:56:29Z","timestamp":1765277789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Convergence of mRNA technology and chimeric antigen receptor therapy: targeted technology optimizing targeted therapy"],"prefix":"10.1186","volume":"23","author":[{"given":"Huajing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5117-2558","authenticated-orcid":false,"given":"Jiaying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"7470_CR1","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024\u201328.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7470_CR2","doi-asserted-by":"publisher","first-page":"2007421","DOI":"10.1002\/adma.202007421","volume":"33","author":"ARK Kumar","year":"2021","unstructured":"Kumar ARK, Shou Y, Chan B, K L, Tay A. Materials for improving immune cell transfection. Adv Mater. 2021;33:2007421. https:\/\/doi.org\/10.1002\/adma.202007421.","journal-title":"Adv Mater"},{"key":"7470_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following car T cell therapy: what we know so far. Nat Rev Clin Oncol. Nature Publishing Group; 2023;20:359\u201371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"7470_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"key":"7470_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390. https:\/\/doi.org\/10.1038\/s41571-022-00689-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"7470_CR6","doi-asserted-by":"publisher","first-page":"101400","DOI":"10.1016\/j.xcrm.2024.101400","volume":"5","author":"Y Huang","year":"2024","unstructured":"Huang Y, Shao M, Teng X, Si X, Wu L, Jiang P, et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep Med. 2024;5:101400. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101400.","journal-title":"Cell Rep Med"},{"key":"7470_CR7","doi-asserted-by":"publisher","first-page":"108350","DOI":"10.1016\/j.biotechadv.2024.108350","volume":"72","author":"L Enriquez-Rodriguez","year":"2024","unstructured":"Enriquez-Rodriguez L, Attia N, Gallego I, Mashal M, Maldonado I, Puras G, et al. Expanding the horizon of transient car T therapeutics using virus-free technology. Biotechnol Adv. 2024;72:108350. https:\/\/doi.org\/10.1016\/j.biotechadv.2024.108350.","journal-title":"Biotechnol Adv"},{"key":"7470_CR8","doi-asserted-by":"publisher","first-page":"2301515","DOI":"10.1002\/adhm.202301515","volume":"12","author":"AG Hamilton","year":"2023","unstructured":"Hamilton AG, Swingle KL, Joseph RA, Mai D, Gong N, Billingsley MM, et al. Ionizable lipid nanoparticles with integrated immune checkpoint inhibition for mRNA car T cell engineering. Adv Healthcare Mater. 2023;12:2301515. https:\/\/doi.org\/10.1002\/adhm.202301515.","journal-title":"Adv Healthcare Mater"},{"key":"7470_CR9","doi-asserted-by":"publisher","unstructured":"Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med. Nature Publishing Group; 2025;1\u201311. https:\/\/doi.org\/10.1038\/s41591-024-03478-6.","DOI":"10.1038\/s41591-024-03478-6"},{"key":"7470_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0031-6997(24)01467-4","volume":"52","author":"WS Hu","year":"2000","unstructured":"Hu WS, Pathak VK. Design of retroviral vectors and helper cells for gene therapy. Pharmacol Rev. 2000;52:493\u2013511.","journal-title":"Pharmacol Rev"},{"key":"7470_CR11","doi-asserted-by":"publisher","unstructured":"W D, Pwl T, G G. Adeno-associated virus vector as a platform for gene therapy delivery. Nature reviews drug discovery [internet]. Nat Rev Drug Discov. 2019;18. https:\/\/doi.org\/10.1038\/s41573-019-0012-9. cited 2025 Feb 10.","DOI":"10.1038\/s41573-019-0012-9"},{"key":"7470_CR12","unstructured":"Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper - PubMed [Internet]. 2025, Feb, 10. https:\/\/webvpn.smu.edu.cn\/https\/536d756973666f726d616c46696d6d75bbdede670083bed7fed31240b4f4d4040a03c709b64c97\/36092368\/. Accessed 10 Feb 2025."},{"key":"7470_CR13","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/s41587-023-01974-7","volume":"42","author":"JA Greig","year":"2024","unstructured":"Greig JA, Martins KM, Breton C, Lamontagne RJ, Zhu Y, He Z, et al. Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration. Nat Biotechnol. 2024;42:1232\u201342. https:\/\/doi.org\/10.1038\/s41587-023-01974-7.","journal-title":"Nat Biotechnol"},{"key":"7470_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","volume":"42","author":"J Wu","year":"2024","unstructured":"Wu J, Wu W, Zhou B, Li B. Chimeric antigen receptor therapy meets mRNA technology. Trends Biotechnol. Elsevier BV; 2024;42:228\u201340. https:\/\/doi.org\/10.1016\/j.tibtech.2023.08.005.","journal-title":"Trends Biotechnol"},{"key":"7470_CR15","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.ymthe.2023.01.021","volume":"31","author":"R Cecchin","year":"2023","unstructured":"Cecchin R, Troyer Z, Witwer K, Morris KV. Extracellular vesicles: the next generation in gene therapy delivery. Mol Ther. 2023;31:1225\u201330. https:\/\/doi.org\/10.1016\/j.ymthe.2023.01.021.","journal-title":"Mol Ther"},{"key":"7470_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short L, Holt RA, Cullis PR, Evgin L. Direct in vivo car T cell engineering. Trends Pharmacological Sci. 2024;45:406\u201318. https:\/\/doi.org\/10.1016\/j.tips.2024.03.004.","journal-title":"Trends Pharmacological Sci"},{"key":"7470_CR17","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 car T cell therapy for refractory systemic lupus erythematosus. Nat Med. Nature Publishing Group; 2022;28:2124\u201332. https:\/\/doi.org\/10.1038\/s41591-022-02017-5.","journal-title":"Nat Med"},{"key":"7470_CR18","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","volume":"30","author":"A Michels","year":"2022","unstructured":"Michels A, Ho N, Buchholz CJ. Precision medicine: in vivo car therapy as a showcase for receptor-targeted vector platforms. Mol Ther. 2022;30:2401\u201315. https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.018.","journal-title":"Mol Ther"},{"key":"7470_CR19","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.3390\/v6124811","volume":"6","author":"JD Suerth","year":"2014","unstructured":"Suerth JD, Labenski V, Schambach A. Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapy. Viruses. Multidisciplinary Digital Publishing Institute; 2014;6:4811\u201338. https:\/\/doi.org\/10.3390\/v6124811.","journal-title":"Viruses"},{"key":"7470_CR20","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1021\/acs.accounts.4c00190","volume":"57","author":"Y Chen","year":"2024","unstructured":"Chen Y, Shokouhi A-R, Voelcker NH, Elnathan R. Nanoinjection: a platform for innovation in ex vivo cell engineering. Acc Chem Res. American Chemical Society; 2024;57:1722\u201335. https:\/\/doi.org\/10.1021\/acs.accounts.4c00190.","journal-title":"Acc Chem Res"},{"key":"7470_CR21","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.1209367109","volume":"109","author":"AJ Geall","year":"2012","unstructured":"Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, et al. Nonviral delivery of self-amplifying rna vaccines. Proc Natl Acad Sci USA. 2012;109:14604\u201309. https:\/\/doi.org\/10.1073\/pnas.1209367109.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7470_CR22","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1182\/bloodadvances.2020002355","volume":"4","author":"AJ Wilk","year":"2020","unstructured":"Wilk AJ, Weidenbacher N-B, Vergara R, Haabeth OAW, Levy R, Waymouth RM, et al. Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy. Blood Adv. 2020;4:4244\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2020002355.","journal-title":"Blood Adv"},{"key":"7470_CR23","doi-asserted-by":"publisher","first-page":"E5859","DOI":"10.1073\/pnas.1805358115","volume":"115","author":"CJ McKinlay","year":"2018","unstructured":"McKinlay CJ, Benner NL, Haabeth OA, Waymouth RM, Wender PA. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proc Natl Acad Sci. 2018;115:E5859\u201366. https:\/\/doi.org\/10.1073\/pnas.1805358115.","journal-title":"Proc Natl Acad Sci"},{"key":"7470_CR24","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1021\/acs.biomac.4c01411","volume":"26","author":"D Koam","year":"2025","unstructured":"Koam D, Park HY, Kim DS, Kwon HJ, Lee Y, Kim K, et al. Amphiphilic polyaspartamide derivatives with cholesterol introduction enhanced ex vivo mRNA transfection efficiency to natural killer cells. Biomacromolecules. American Chemical Society; 2025;26:1086\u201397. https:\/\/doi.org\/10.1021\/acs.biomac.4c01411.","journal-title":"Biomacromolecules"},{"key":"7470_CR25","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1021\/acscentsci.9b00843","volume":"5","author":"HJ Kim","year":"2019","unstructured":"Kim HJ, Ogura S, Otabe T, Kamegawa R, Sato M, Kataoka K, et al. Fine-tuning of Hydrophobicity in Amphiphilic Polyaspartamide derivatives for rapid and transient expression of messenger rna directed toward genome engineering in brain. ACS Cent Sci. 2019;5:1866\u201375. https:\/\/doi.org\/10.1021\/acscentsci.9b00843.","journal-title":"ACS Cent Sci"},{"key":"7470_CR26","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/biomedicines10112885","volume":"10","author":"SK Georgiou-Siafis","year":"2022","unstructured":"Georgiou-Siafis SK, Miliotou AN, Ntenti C, Pappas IS, Papadopoulou LC. An innovative PTD-IVT-mRNA delivery platform for car immunotherapy of ErbB(+) solid tumor Neoplastic cells. Biomedicines. 2022;10:2885. https:\/\/doi.org\/10.3390\/biomedicines10112885.","journal-title":"Biomedicines"},{"key":"7470_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jcyt.2023.01.005","volume":"25","author":"K Si","year":"2023","unstructured":"Si K, Dai Z, Li Z, Ye Z, Ding B, Feng S, et al. Engineered exosome-mediated messenger rna and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering. Cytotherapy. 2023;25:615\u201324. https:\/\/doi.org\/10.1016\/j.jcyt.2023.01.005.","journal-title":"Cytotherapy"},{"key":"7470_CR28","doi-asserted-by":"publisher","unstructured":"Rodriguez N, Hofmann C, Yang OO, Gelbart WM. A new approach to in vivo transformation of killer T cells. J Mol Biol. 2025;169369. https:\/\/doi.org\/10.1016\/j.jmb.2025.169369.","DOI":"10.1016\/j.jmb.2025.169369"},{"key":"7470_CR29","doi-asserted-by":"publisher","first-page":"100011","DOI":"10.1016\/j.celbio.2025.100011","volume":"1","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yang M, Zhang B-Y, Zhao G, Zhou S-K, Lu Z-D, et al. Leveraging T cell-specific fusogenicity of HIV for in vivo mRNA delivery to produce human CAR-T cells. Cell Biomater. 2025;1:100011. https:\/\/doi.org\/10.1016\/j.celbio.2025.100011.","journal-title":"Cell Biomater"},{"key":"7470_CR30","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3109\/10428194.2011.634048","volume":"53","author":"L Boissel","year":"2012","unstructured":"Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van Etten RA, et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leukemia Lymphoma. Taylor & Francis; 2012;53:958\u201365. https:\/\/doi.org\/10.3109\/10428194.2011.634048.","journal-title":"Leukemia Lymphoma"},{"key":"7470_CR31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41551-023-01073-7","volume":"8","author":"J An","year":"2024","unstructured":"An J, Zhang C-P, Qiu H-Y, Zhang H-X, Chen Q-B, Zhang Y-M, et al. Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS\u2013STING pathway. Nat Biomed Eng. Nature Publishing Group; 2024;8:149\u201364. https:\/\/doi.org\/10.1038\/s41551-023-01073-7.","journal-title":"Nat Biomed Eng"},{"key":"7470_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-022-03326-6","volume":"20","author":"G Roex","year":"2022","unstructured":"Roex G, Campillo-Davo D, Flumens D, Shaw PAG, Krekelbergh L, De Reu H, et al. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. J Transl Med. 2022;20:124. https:\/\/doi.org\/10.1186\/s12967-022-03326-6.","journal-title":"J Transl Med"},{"key":"7470_CR33","doi-asserted-by":"publisher","first-page":"1900133","DOI":"10.1002\/adtp.201900133","volume":"2","author":"A Tay","year":"2019","unstructured":"Tay A, Melosh N. Transfection with nanostructure electro-injection is minimally perturbative. Adv Ther (Weinh). 2019;2:1900133. https:\/\/doi.org\/10.1002\/adtp.201900133.","journal-title":"Adv Ther (Weinh)"},{"key":"7470_CR34","doi-asserted-by":"publisher","first-page":"E10907","DOI":"10.1073\/pnas.1809671115","volume":"115","author":"T DiTommaso","year":"2018","unstructured":"DiTommaso T, Cole JM, Cassereau L, Bugg\u00e9 JA, Hanson JLS, Bridgen DT, et al. Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo. Proc Natl Acad Sci USA. 2018;115:E10907\u201314. https:\/\/doi.org\/10.1073\/pnas.1809671115.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7470_CR35","doi-asserted-by":"publisher","first-page":"2304122","DOI":"10.1002\/adma.202304122","volume":"35","author":"A Shokouhi","year":"2023","unstructured":"Shokouhi A, Chen Y, Yoh HZ, Brenker J, Alan T, Murayama T, et al. Engineering efficient CAR-T cells via Electroactive Nanoinjection. Adv Mater. 2023;35:2304122. https:\/\/doi.org\/10.1002\/adma.202304122.","journal-title":"Adv Mater"},{"key":"7470_CR36","doi-asserted-by":"publisher","first-page":"2303261","DOI":"10.1002\/adma.202303261","volume":"35","author":"Y Zong","year":"2023","unstructured":"Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater. 2023;35:2303261. https:\/\/doi.org\/10.1002\/adma.202303261.","journal-title":"Adv Mater"},{"key":"7470_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/thno.89913","volume":"14","author":"SK Patel","year":"2024","unstructured":"Patel SK, Billingsley MM, Mukalel AJ, Thatte AS, Hamilton AG, Gong N, et al. Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery. Theranostics. 2024;14:1\u201316. https:\/\/doi.org\/10.7150\/thno.89913.","journal-title":"Theranostics"},{"key":"7470_CR38","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","volume":"20","author":"MM Billingsley","year":"2020","unstructured":"Billingsley MM, Singh N, Ravikumar P, Zhang R, June CH, Mitchell MJ. Ionizable lipid nanoparticle-mediated mRNA delivery for human car T cell engineering. Nano Lett. 2020;20:1578\u201389. https:\/\/doi.org\/10.1021\/acs.nanolett.9b04246.","journal-title":"Nano Lett"},{"key":"7470_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","volume":"22","author":"MM Billingsley","year":"2022","unstructured":"Billingsley MM, Hamilton AG, Mai D, Patel SK, Swingle KL, Sheppard NC, et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of car T cells. Nano Lett. 2022;22:533\u201342. https:\/\/doi.org\/10.1021\/acs.nanolett.1c02503.","journal-title":"Nano Lett"},{"key":"7470_CR40","doi-asserted-by":"publisher","first-page":"2409812","DOI":"10.1002\/adma.202409812","volume":"36","author":"Y Fei","year":"2024","unstructured":"Fei Y, Yu X, Liu P, Ren H, Wei T, Cheng Q. Simplified lipid Nanoparticles for tissue- and cell-targeted mRNA delivery facilitate precision tumor therapy in a lung metastasis mouse Model. Adv Mater. 2024;36:2409812. https:\/\/doi.org\/10.1002\/adma.202409812.","journal-title":"Adv Mater"},{"key":"7470_CR41","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1021\/acsbiomaterials.1c01532","volume":"8","author":"Z Ye","year":"2022","unstructured":"Ye Z, Chen J, Zhao X, Li Y, Harmon J, Huang C, et al. In vitro engineering chimeric antigen receptor Macrophages and T cells by lipid nanoparticle-mediate mRNA delivery. ACS Biomater Sci Eng. American Chemical Society; 2022;8:722\u201333. https:\/\/doi.org\/10.1021\/acsbiomaterials.1c01532.","journal-title":"ACS Biomater Sci Eng"},{"key":"7470_CR42","doi-asserted-by":"publisher","first-page":"2313226","DOI":"10.1002\/adma.202313226","volume":"36","author":"AE Metzloff","year":"2024","unstructured":"Metzloff AE, Padilla MS, Gong N, Billingsley MM, Han X, Merolle M, et al. Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy. Adv Mater. 2024;36:2313226. https:\/\/doi.org\/10.1002\/adma.202313226.","journal-title":"Adv Mater"},{"key":"7470_CR43","doi-asserted-by":"publisher","first-page":"9199","DOI":"10.3390\/ijms26189199","volume":"26","author":"J Fu","year":"2025","unstructured":"Fu J, Zhang Y, Lv Y, Li R, Gu H, Yang J. A bioactive lipid nanoparticle integrating arachidonic acid enables high-efficiency mRNA delivery and potent CAR-Macrophage engineering. Int J Mol Sci. Multidisciplinary Digital Publishing Institute; 2025;26:9199. https:\/\/doi.org\/10.3390\/ijms26189199.","journal-title":"Int J Mol Sci"},{"key":"7470_CR44","doi-asserted-by":"publisher","first-page":"102209","DOI":"10.1016\/j.xcrm.2025.102209","volume":"6","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Ma B, Li B, Li Z, Gao M, Zhao H, et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Rep Med. 2025;6:102209. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102209.","journal-title":"Cell Rep Med"},{"key":"7470_CR45","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.bbamem.2010.09.001","volume":"1798","author":"R Brasseur","year":"2010","unstructured":"Brasseur R, Divita G. Happy birthday cell penetrating peptides: already 20 years. Biochim Biophys Acta. 2010;1798:2177\u201381. https:\/\/doi.org\/10.1016\/j.bbamem.2010.09.001.","journal-title":"Biochim Biophys Acta"},{"key":"7470_CR46","doi-asserted-by":"publisher","unstructured":"Lc P, A I-T, Cn M, Ld T, Ed S, Gi G, et al. Production and transduction of a human recombinant \u03b2-globin Chain into Proerythroid K-562 cells to replace missing endogenous \u03b2-globin. Mol Pharm. 2018;15. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00857. cited 2025 Feb 12.","DOI":"10.1021\/acs.molpharmaceut.8b00857"},{"key":"7470_CR47","doi-asserted-by":"publisher","unstructured":"An M, P D, V E, S M, L D, T S, et al. PTD-mediated delivery of \u03b1-globin chain into \u039a-562 erythroleukemia cells and \u03b1-thalassemic (HBH) patients\u2019 RBCs ex vivo in the frame of protein replacement therapy. J Biol Res (thessalon). 2021;28. https:\/\/doi.org\/10.1186\/s40709-021-00148-3. cited 2025 Feb 12.","DOI":"10.1186\/s40709-021-00148-3"},{"key":"7470_CR48","doi-asserted-by":"publisher","unstructured":"Foltopoulou PF, Tsiftsoglou AS, Bonovolias ID, Ingendoh AT, Papadopoulou LC. Intracellular delivery of full length recombinant human mitochondrial L-Sco2 protein into the mitochondria of permanent cell lines and SCO2 deficient patient\u2019s primary cells. Biochim Biophys Acta. 2010 [cited 2025 Feb 12];1802. https:\/\/doi.org\/10.1016\/j.bbadis.2010.02.009.","DOI":"10.1016\/j.bbadis.2010.02.009"},{"key":"7470_CR49","unstructured":"Cardioprotection against myocardial infarction with PTD-BIR3\/RING, a XIAP mimicking protein - PubMed [internet]. 2025 Feb 12. https:\/\/webvpn.smu.edu.cn\/https\/536d756973666f726d616c46696d6d75bbdede670083bed7fed31240b4f4d4040a03c709b64c97\/19233193\/. Accessed 12 Feb 2025."},{"key":"7470_CR50","unstructured":"Newly designed protein transduction domain (PTD)-mediated BMP-7 is a potential therapeutic for peritoneal fibrosis - PubMed [internet]. 2025 Feb 12. https:\/\/webvpn.smu.edu.cn\/https\/536d756973666f726d616c46696d6d75bbdede670083bed7fed31240b4f4d4040a03c709b64c97\/33079436\/. Accessed 12 Feb 2025."},{"key":"7470_CR51","doi-asserted-by":"publisher","unstructured":"An M, Is P, S G, V E, As T, Is V, et al. Development of a novel PTD-mediated IVT-mRNA delivery platform for potential protein replacement therapy of metabolic\/genetic disorders. Mol Ther Nucleic Acids. 2021;26. https:\/\/doi.org\/10.1016\/j.omtn.2021.09.008. cited 2025 Feb 12.","DOI":"10.1016\/j.omtn.2021.09.008"},{"key":"7470_CR52","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/0008-5472.CAN-17-2880","volume":"78","author":"Y Wan","year":"2018","unstructured":"Wan Y, Wang L, Zhu C, Zheng Q, Wang G, Tong J, et al. Aptamer-conjugated extracellular Nanovesicles for targeted drug delivery. Cancer Res. 2018;78:798\u2013808. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2880.","journal-title":"Cancer Res"},{"key":"7470_CR53","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/cr.2017.62","volume":"27","author":"B Xu","year":"2017","unstructured":"Xu B, Zhang Y, Du X-F, Li J, Zi H-X, Bu J-W, et al. Neurons secrete miR-132-containing exosomes to regulate brain vascular integrity. Cell Res. Nature Publishing Group; 2017;27:882\u201397. https:\/\/doi.org\/10.1038\/cr.2017.62.","journal-title":"Cell Res"},{"key":"7470_CR54","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.2147\/IJN.S231214","volume":"15","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Zhang H, Ning T, Liu D, Deng T, Liu R, et al. Exosome-delivered c-met siRNA could reverse chemoresistance to cisplatin in gastric cancer. IJN. Dove Press; 2020;15:2323\u201335. https:\/\/doi.org\/10.2147\/IJN.S231214.","journal-title":"IJN"},{"key":"7470_CR55","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.1039\/C9NR01255A","volume":"11","author":"H Wang","year":"2019","unstructured":"Wang H, Sui H, Zheng Y, Jiang Y, Shi Y, Liang J, et al. Curcumin-primed exosomes potently ameliorate cognitive function in ad mice by inhibiting hyperphosphorylation of the Tau protein through the AKT\/GSK-3\u03b2 pathway. Nanoscale. The Royal Society of Chemistry; 2019;11:7481\u201396. https:\/\/doi.org\/10.1039\/C9NR01255A.","journal-title":"Nanoscale"},{"key":"7470_CR56","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","volume":"29","author":"I Tomb\u00e1cz","year":"2021","unstructured":"Tomb\u00e1cz I, Laczk\u00f3 D, Shahnawaz H, Muramatsu H, Natesan A, Yadegari A, et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Mol Ther. 2021;29:3293\u2013304. https:\/\/doi.org\/10.1016\/j.ymthe.2021.06.004.","journal-title":"Mol Ther"},{"key":"7470_CR57","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","volume":"360","author":"Z Yang","year":"2023","unstructured":"Yang Z, Liu Y, Zhao K, Jing W, Gao L, Dong X, et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced car macrophages augments hepatocellular carcinoma immunotherapy. J Control Release. 2023;360:718\u201333. https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.021.","journal-title":"J Control Release"},{"key":"7470_CR58","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1021\/acsnano.3c10109","volume":"18","author":"C Tang","year":"2024","unstructured":"Tang C, Jing W, Han K, Yang Z, Zhang S, Liu M, et al. mRNA-laden lipid-nanoparticle-enabled in situ CAR-Macrophage engineering for the eradication of Multidrug-resistant bacteria in a sepsis mouse Model. ACS Nano. 2024;18:2261\u201378. https:\/\/doi.org\/10.1021\/acsnano.3c10109.","journal-title":"ACS Nano"},{"key":"7470_CR59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, M\u00e9ndez Fern\u00e1ndez PO, Shewale SV, Li L, et al. Car T cells produced in vivo to treat cardiac injury. Science. 2022;375:91\u201396. https:\/\/doi.org\/10.1126\/science.abm0594.","journal-title":"Science"},{"key":"7470_CR60","doi-asserted-by":"publisher","first-page":"e202310395","DOI":"10.1002\/anie.202310395","volume":"62","author":"E \u00c1lvarez-Benedicto","year":"2023","unstructured":"\u00c1lvarez-Benedicto E, Tian Z, Chatterjee S, Orlando D, Kim M, Guerrero ED, et al. Spleen sort LNP generated in situ car T cells extend survival in a mouse Model of lymphoreplete B cell lymphoma. Angew Chem Int Ed. 2023;62:e202310395. https:\/\/doi.org\/10.1002\/anie.202310395.","journal-title":"Angew Chem Int Ed"},{"key":"7470_CR61","doi-asserted-by":"publisher","first-page":"121339","DOI":"10.1016\/j.biomaterials.2021.121339","volume":"281","author":"A Kheirolomoom","year":"2022","unstructured":"Kheirolomoom A, Kare AJ, Ingham ES, Paulmurugan R, Robinson ER, Baikoghli M, et al. In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift. Biomaterials. 2022;281:121339. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121339.","journal-title":"Biomaterials"},{"key":"7470_CR62","doi-asserted-by":"publisher","first-page":"2304378","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, Gong N, Mukalel AJ, Thatte AS, El-Mayta R, Patel SK, et al. In vivo mRNA car T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20:2304378. https:\/\/doi.org\/10.1002\/smll.202304378.","journal-title":"Small"},{"key":"7470_CR63","unstructured":"Hunter TL, Zhang Y, Matsuda D, Riener R, Wang A, Li JJ, et al. In vivo car T cell generation to treat cancer and autoimmune disease."},{"key":"7470_CR64","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41565-025-01954-9","volume":"20","author":"MZ Chen","year":"2025","unstructured":"Chen MZ, Yuen D, McLeod VM, Yong KW, Smyth CH, Herling BR, et al. A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles. Nat Nanotechnol. 2025;20:1273\u201384. https:\/\/doi.org\/10.1038\/s41565-025-01954-9.","journal-title":"Nat Nanotechnol"},{"key":"7470_CR65","doi-asserted-by":"publisher","first-page":"2312038","DOI":"10.1002\/adfm.202312038","volume":"34","author":"AJ Mukalel","year":"2024","unstructured":"Mukalel AJ, Hamilton AG, Billingsley MM, Li J, Thatte AS, Han X, et al. Oxidized mRNA lipid nanoparticles for in situ chimeric antigen receptor monocyte engineering. Adv Funct Mater. 2024;34:2312038. https:\/\/doi.org\/10.1002\/adfm.202312038.","journal-title":"Adv Funct Mater"},{"key":"7470_CR66","doi-asserted-by":"publisher","first-page":"1501365","DOI":"10.3389\/fimmu.2024.1501365","volume":"15","author":"S Argueta","year":"2024","unstructured":"Argueta S, Wang Y, Zhao H, Diwanji N, Gorgievski M, Cochran E, et al. In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models. Front Immunol. 2024;15:1501365. https:\/\/doi.org\/10.3389\/fimmu.2024.1501365.","journal-title":"Front Immunol"},{"key":"7470_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. Nature Publishing Group; 2020;11:1\u201317. https:\/\/doi.org\/10.1038\/s41467-020-19486-2.","journal-title":"Nat Commun"},{"key":"7470_CR68","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1080\/17425247.2020.1796628","volume":"17","author":"J Karlsson","year":"2020","unstructured":"Karlsson J, Rhodes KR, Green JJ, Tzeng SY. Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities. Expert Opin Drug Deliv. 2020;17:1395\u2013410. https:\/\/doi.org\/10.1080\/17425247.2020.1796628.","journal-title":"Expert Opin Drug Deliv"},{"key":"7470_CR69","doi-asserted-by":"publisher","first-page":"eaay3255","DOI":"10.1126\/sciadv.aay3255","volume":"5","author":"Y Rui","year":"2019","unstructured":"Rui Y, Wilson DR, Choi J, Varanasi M, Sanders K, Karlsson J, et al. Carboxylated branched poly(\u03b2-amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci Adv. American Association for the Advancement of Science; 2019;5:eaay3255. https:\/\/doi.org\/10.1126\/sciadv.aay3255.","journal-title":"Sci Adv"},{"key":"7470_CR70","doi-asserted-by":"publisher","first-page":"14785","DOI":"10.1021\/jacs.4c02704","volume":"146","author":"Z Li","year":"2024","unstructured":"Li Z, Amaya L, Ee A, Wang SK, Ranjan A, Waymouth RM, et al. Organ- and cell-selective delivery of mRNA in vivo using guanidinylated serinol charge-altering releasable transporters. J Am Chem Soc. 2024;146:14785\u201398. https:\/\/doi.org\/10.1021\/jacs.4c02704.","journal-title":"J Am Chem Soc"},{"key":"7470_CR71","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.1038\/s41467-025-62506-2","volume":"16","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Zhu T, Chen Z, Huang X. Lung metastasis and recurrence is mitigated by car macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles. Nat Commun. 2025;16:7166. https:\/\/doi.org\/10.1038\/s41467-025-62506-2.","journal-title":"Nat Commun"},{"key":"7470_CR72","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1002\/anie.201611783","volume":"56","author":"C Qian","year":"2017","unstructured":"Qian C, Feng P, Yu J, Chen Y, Hu Q, Sun W, et al. Anaerobe-Inspired anticancer Nanovesicles. Angew Chem Int Ed. 2017;56:2588\u201393. https:\/\/doi.org\/10.1002\/anie.201611783.","journal-title":"Angew Chem Int Ed"},{"key":"7470_CR73","doi-asserted-by":"crossref","unstructured":"Jiang X-C. The in vivo fate and targeting engineering of crossover vesicle-based gene delivery system. 2022.","DOI":"10.1016\/j.addr.2022.114324"},{"key":"7470_CR74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s43586-023-00246-7","volume":"3","author":"S Chen","year":"2023","unstructured":"Chen S, Huang X, Xue Y, \u00c1lvarez-Benedicto E, Shi Y, Chen W, et al. Nanotechnology-based mRNA vaccines. Nat Rev Methods Primers. 2023;3:63. https:\/\/doi.org\/10.1038\/s43586-023-00246-7.","journal-title":"Nat Rev Methods Primers"},{"key":"7470_CR75","unstructured":"Wang Y, Xu L, Wu Y, Ma S, Ying N, Yang Y. Production of pantropic retrovirus by ecotropic packaging cell line research article. 2014 [cited 2025 Nov 2]. https:\/\/www.semanticscholar.org\/paper\/Production-of-pantropic-retrovirus-by-ecotropic-Wang-Xu\/3e18bd24fb4500a5236743d3a89e064fd5aad378. Accessed 2 Nov 2025."},{"key":"7470_CR76","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41551-023-01058-6","volume":"8","author":"L Ye","year":"2024","unstructured":"Ye L, Lam SZ, Yang L, Suzuki K, Zou Y, Lin Q, et al. AAV-mediated delivery of a sleeping beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells. Nat Biomed Eng. Nature Publishing Group; 2024;8:132\u201348. https:\/\/doi.org\/10.1038\/s41551-023-01058-6.","journal-title":"Nat Biomed Eng"},{"key":"7470_CR77","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12967-024-04990-6","volume":"22","author":"N Yang","year":"2024","unstructured":"Yang N, Zhang C, Zhang Y, Fan Y, Zhang J, Lin X, et al. CD19\/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. J Transl Med. 2024;22:274. https:\/\/doi.org\/10.1186\/s12967-024-04990-6.","journal-title":"J Transl Med"},{"key":"7470_CR78","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu B, Ren J, Luo Y, Keith B, Young RM, Scholler J, et al. Augmentation of antitumor immunity by human and mouse car T cells secreting IL-18. Cell Rep. 2017;20:3025\u201333. https:\/\/doi.org\/10.1016\/j.celrep.2017.09.002.","journal-title":"Cell Rep"},{"key":"7470_CR79","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccell.2017.01.004","volume":"31","author":"KV Katlinski","year":"2017","unstructured":"Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell. 2017;31:194\u2013207. https:\/\/doi.org\/10.1016\/j.ccell.2017.01.004.","journal-title":"Cancer Cell"},{"key":"7470_CR80","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-21-4384","volume":"28","author":"H Meister","year":"2022","unstructured":"Meister H, Look T, Roth P, Pascolo S, Sahin U, Lee S, et al. Multifunctional mRNA-based car T cells display promising antitumor activity against glioblastoma. Clin Cancer Res. 2022;28:4747\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4384.","journal-title":"Clin Cancer Res"},{"key":"7470_CR81","doi-asserted-by":"publisher","first-page":"100978","DOI":"10.1016\/j.xcrm.2023.100978","volume":"4","author":"I Olivera","year":"2023","unstructured":"Olivera I, Bola\u00f1os E, Gonzalez-Gomariz J, Hervas-Stubbs S, Mari\u00f1o KV, Luri-Rey C, et al. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. Cell Rep Med. 2023;4:100978. https:\/\/doi.org\/10.1016\/j.xcrm.2023.100978.","journal-title":"Cell Rep Med"},{"key":"7470_CR82","doi-asserted-by":"publisher","first-page":"2206856","DOI":"10.1002\/advs.202206856","volume":"10","author":"S Huang","year":"2023","unstructured":"Huang S, Pan C, Lin Y, Chen M, Chen Y, Jan C, et al. BiTE-Secreting CAR-\u03b3\u03b4T as a dual targeting strategy for the treatment of solid tumors. Adv Sci (Weinh). 2023;10:2206856. https:\/\/doi.org\/10.1002\/advs.202206856.","journal-title":"Adv Sci (Weinh)"},{"key":"7470_CR83","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"J Zhou","year":"2022","unstructured":"Zhou J, Sun L, Jia Y, Wang Z, Luo T, Tan J, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307. https:\/\/doi.org\/10.1016\/j.jconrel.2022.08.033.","journal-title":"J Control Release"},{"key":"7470_CR84","doi-asserted-by":"publisher","first-page":"e438.1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector cell-associated Hemophagocytic Lymphohistiocytosis-like syndrome. Transplant Cellular Ther. 2023;29:.e438.1\u2013438.16. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006.","journal-title":"Transplant Cellular Ther"},{"key":"7470_CR85","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, et al. Safety and efficacy of Intratumoral injections of chimeric antigen receptor (car) T cells in metastatic breast cancer. Cancer Immunol Res. 2017;5:1152\u201361. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0189.","journal-title":"Cancer Immunol Res"},{"key":"7470_CR86","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","volume":"27","author":"L Xiao","year":"2019","unstructured":"Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H, et al. Adoptive transfer of NKG2D car mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther. Elsevier; 2019;27:1114\u201325. https:\/\/doi.org\/10.1016\/j.ymthe.2019.03.011.","journal-title":"Mol Ther"},{"key":"7470_CR87","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2:112\u201320. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0170.","journal-title":"Cancer Immunol Res"},{"key":"7470_CR88","doi-asserted-by":"publisher","first-page":"114961","DOI":"10.1016\/j.addr.2023.114961","volume":"199","author":"DD Kang","year":"2023","unstructured":"Kang DD, Li H, Dong Y. Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics. Adv Drug Delivery Rev. 2023;199:114961. https:\/\/doi.org\/10.1016\/j.addr.2023.114961.","journal-title":"Adv Drug Delivery Rev"},{"key":"7470_CR89","unstructured":"Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel \u201canti-reverse\u201d cap analogs 7-methyl(39-O-methyl)GpppG and 7-methyl(39-deoxy)gpppg."},{"key":"7470_CR90","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines \u2014 a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261\u201379. https:\/\/doi.org\/10.1038\/nrd.2017.243.","journal-title":"Nat Rev Drug Discov"},{"key":"7470_CR91","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4161\/rna.22269","volume":"9","author":"T Schlake","year":"2012","unstructured":"Schlake T, Thess A, Fotin-Mleczek M, Kallen K-J. Developing mRNA-vaccine technologies. RNA Biol. 2012;9:1319\u201330. https:\/\/doi.org\/10.4161\/rna.22269.","journal-title":"RNA Biol"},{"key":"7470_CR92","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3 K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields Superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16:1833\u201340. https:\/\/doi.org\/10.1038\/mt.2008.200.","journal-title":"Mol Ther"},{"key":"7470_CR93","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","volume":"371","author":"C Krienke","year":"2021","unstructured":"Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. American Association for the Advancement of Science; 2021;371:145\u201353. https:\/\/doi.org\/10.1126\/science.aay3638.","journal-title":"Science"},{"key":"7470_CR94","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1021\/acs.bioconjchem.6b00090","volume":"27","author":"B Li","year":"2016","unstructured":"Li B, Luo X, Dong Y. Effects of chemically modified Messenger rna on protein expression. Bioconjugate Chem. American Chemical Society; 2016;27:849\u201353. https:\/\/doi.org\/10.1021\/acs.bioconjchem.6b00090.","journal-title":"Bioconjugate Chem"},{"key":"7470_CR95","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4939-6481-9_6","volume":"1499","author":"N Pardi","year":"2017","unstructured":"Pardi N, Weissman D. Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol Biol. 2017;1499:109\u201321. https:\/\/doi.org\/10.1007\/978-1-4939-6481-9_6.","journal-title":"Methods Mol Biol"},{"key":"7470_CR96","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41467-021-20903-3","volume":"12","author":"F Rizvi","year":"2021","unstructured":"Rizvi F, Everton E, Smith AR, Liu H, Osota E, Beattie M, et al. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun. 2021;12:613. https:\/\/doi.org\/10.1038\/s41467-021-20903-3.","journal-title":"Nat Commun"},{"key":"7470_CR97","doi-asserted-by":"publisher","first-page":"21150","DOI":"10.1073\/pnas.1906182116","volume":"116","author":"B Truong","year":"2019","unstructured":"Truong B, Allegri G, Liu X-B, Burke KE, Zhu X, Cederbaum SD, et al. Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency. Proc Natl Acad Sci. 2019;116:21150\u201359. https:\/\/doi.org\/10.1073\/pnas.1906182116.","journal-title":"Proc Natl Acad Sci"},{"key":"7470_CR98","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. Nature Publishing Group; 2023;621:396\u2013403. https:\/\/doi.org\/10.1038\/s41586-023-06127-z.","journal-title":"Nature"},{"key":"7470_CR99","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature11928","volume":"495","author":"S Memczak","year":"2013","unstructured":"Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333\u201338. https:\/\/doi.org\/10.1038\/nature11928.","journal-title":"Nature"},{"key":"7470_CR100","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nsmb.2959","volume":"22","author":"Z Li","year":"2015","unstructured":"Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. Nature Publishing Group; 2015;22:256\u201364. https:\/\/doi.org\/10.1038\/nsmb.2959.","journal-title":"Nat Struct Mol Biol"},{"key":"7470_CR101","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrg.2017.27","volume":"18","author":"L Koch","year":"2017","unstructured":"Koch L. Translated circular RNAs. Nat Rev Genet. 2017;18:272\u201373. https:\/\/doi.org\/10.1038\/nrg.2017.27.","journal-title":"Nat Rev Genet"},{"key":"7470_CR102","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molcel.2017.02.021","volume":"66","author":"NR Pamudurti","year":"2017","unstructured":"Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, et al. Translation of CircRNAs. Mol Cell. Elsevier; 2017;66:9\u201321.e7. https:\/\/doi.org\/10.1016\/j.molcel.2017.02.021.","journal-title":"Mol Cell"},{"key":"7470_CR103","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molcel.2017.02.017","volume":"66","author":"I Legnini","year":"2017","unstructured":"Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, et al. Circ-ZNF609 is a circular rna that Can Be translated and functions in Myogenesis. Mol Cell. 2017;66:22\u201337.e9. https:\/\/doi.org\/10.1016\/j.molcel.2017.02.017.","journal-title":"Mol Cell"},{"key":"7470_CR104","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/nar\/gkv1367","volume":"44","author":"Y Enuka","year":"2016","unstructured":"Enuka Y, Lauriola M, Feldman ME, Sas-Chen A, Ulitsky I, Yarden Y. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res. 2016;44:1370\u201383. https:\/\/doi.org\/10.1093\/nar\/gkv1367.","journal-title":"Nucleic Acids Res"},{"key":"7470_CR105","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","volume":"9","author":"RA Wesselhoeft","year":"2018","unstructured":"Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular rna for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9:2629. https:\/\/doi.org\/10.1038\/s41467-018-05096-6.","journal-title":"Nat Commun"},{"key":"7470_CR106","doi-asserted-by":"publisher","unstructured":"Hu Q, Zhao H, Zhou K, Hua X, Zhang X. Scarless circular mRNA-based CAR-T cell therapy elicits superior anti-tumor efficacy [internet]. bioRxiv;. 2024;2024.08.05.606578. https:\/\/doi.org\/10.1101\/2024.08.05.606578. cited 2025 Feb 3.","DOI":"10.1101\/2024.08.05.606578"},{"key":"7470_CR107","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14:73. https:\/\/doi.org\/10.1186\/s13045-021-01083-5.","journal-title":"J Hematol Oncol"},{"key":"7470_CR108","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41467-017-00505-8","volume":"8","author":"HF Moffett","year":"2017","unstructured":"Moffett HF, Coon ME, Radtke S, Stephan SB, McKnight L, Lambert A, et al. Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers. Nat Commun. Nature Publishing Group; 2017;8:389. https:\/\/doi.org\/10.1038\/s41467-017-00505-8.","journal-title":"Nat Commun"},{"key":"7470_CR109","doi-asserted-by":"publisher","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","volume":"139","author":"Y Chen","year":"2021","unstructured":"Chen Y, Yu Z, Tan X, Jiang H, Xu Z, Fang Y, et al. CAR-macrophage: a new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021;139:111605. https:\/\/doi.org\/10.1016\/j.biopha.2021.111605.","journal-title":"Biomed Pharmacother"},{"key":"7470_CR110","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","volume":"32","author":"Z Chen","year":"2024","unstructured":"Chen Z, Shu J, Hu Y, Mei H. Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy. Mol Ther. 2024;32:3772\u201392. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.019.","journal-title":"Mol Ther"},{"key":"7470_CR111","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","volume":"10","author":"F Zhang","year":"2019","unstructured":"Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun. 2019;10:3974. https:\/\/doi.org\/10.1038\/s41467-019-11911-5.","journal-title":"Nat Commun"},{"key":"7470_CR112","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger A, Kramer M, R\u00f6llig C, Thiede C, Bornh\u00e4user M, von Bonin M, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. Nature Publishing Group; 2014;4:e218\u2013218. https:\/\/doi.org\/10.1038\/bcj.2014.39.","journal-title":"Blood Cancer J"},{"key":"7470_CR113","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/cancers13030496","volume":"13","author":"VM Perriello","year":"2021","unstructured":"Perriello VM, Gionfriddo I, Rossi R, Milano F, Mezzasoma F, Marra A, et al. CD123 is consistently expressed on NPM1-mutated AML cells. Cancers. Multidisciplinary Digital Publishing Institute; 2021;13:496. https:\/\/doi.org\/10.3390\/cancers13030496.","journal-title":"Cancers"},{"key":"7470_CR114","doi-asserted-by":"publisher","unstructured":"Santos Azevedo R, Wang SA, Daver NG, Pemmaraju N, Kadia TM, Issa GC, et al. CD123 expression and its correlation with mutation profile in acute myeloid leukemia. JCO [Internet]. 2025;43. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e18524. cited 2025 Oct 29.","DOI":"10.1200\/JCO.2025.43.16_suppl.e18524"},{"key":"7470_CR115","doi-asserted-by":"publisher","unstructured":"Xu X, Sinha L, Singh A, Yang C, Xiang J, Tichauer KM. In: Farkas DL, Nicolau DV, Leif RC, editors.. Quantification of cell surface receptor expression in live tissue culture media using a dual-tracer stain and rinse approach. San Francisco, California, United States; 2015. p. 932814. cited 2025 Oct 29. https:\/\/doi.org\/10.1117\/12.2078472.","DOI":"10.1117\/12.2078472"},{"key":"7470_CR116","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.lungcan.2011.07.009","volume":"75","author":"A Ziegler","year":"2012","unstructured":"Ziegler A, Cerciello F, Bigosch C, Bausch-Fluck D, Felley-Bosco E, Ossola R, et al. Proteomic surfaceome analysis of mesothelioma. Lung Cancer. 2012;75:189\u201396. https:\/\/doi.org\/10.1016\/j.lungcan.2011.07.009.","journal-title":"Lung Cancer"},{"key":"7470_CR117","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","volume":"41","author":"A Gottschlich","year":"2023","unstructured":"Gottschlich A, Thomas M, Gr\u00fcnmeier R, Lesch S, Rohrbacher L, Igl V, et al. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol. Nature Publishing Group; 2023;41:1618\u201332. https:\/\/doi.org\/10.1038\/s41587-023-01684-0.","journal-title":"Nat Biotechnol"},{"key":"7470_CR118","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2018-03-837609","volume":"132","author":"J Svoboda","year":"2018","unstructured":"Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, et al. Nonviral rna chimeric antigen receptor\u2013modified T cells in patients with Hodgkin lymphoma. Blood. 2018;132:1022\u201326. https:\/\/doi.org\/10.1182\/blood-2018-03-837609.","journal-title":"Blood"},{"key":"7470_CR119","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/CIRCRESAHA.125.326716","volume":"137","author":"H Du","year":"2025","unstructured":"Du H, You X, Zhang J, Liu S, Zhou Y, Wang Y, et al. Car macrophages engineered in vivo for attenuating myocardial ischemia-reperfusion injury. Circ Res. 2025;137:846\u201359. https:\/\/doi.org\/10.1161\/CIRCRESAHA.125.326716.","journal-title":"Circ Res"},{"key":"7470_CR120","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/BF00146079","volume":"27","author":"ME Berens","year":"1996","unstructured":"Berens ME, Rief MD, Shapiro JR, Haskett D, Giese A, Joy A, et al. Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression. J Neurooncol. 1996;27:11\u201322. https:\/\/doi.org\/10.1007\/BF00146079.","journal-title":"J Neurooncol"},{"key":"7470_CR121","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3892\/ijo.2011.1287","volume":"40","author":"A Guillaudeau","year":"2012","unstructured":"Guillaudeau A, Durand K, Rabinovitch-Chable H, Pommepuy I, Mesturoux L, Robert S, et al. Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain. Int J Oncol. 2012;40:1142\u201352. https:\/\/doi.org\/10.3892\/ijo.2011.1287.","journal-title":"Int J Oncol"},{"key":"7470_CR122","doi-asserted-by":"publisher","unstructured":"Aminov S, Giricz O, Melnekoff DT, Sica RA, Polishchuk V, Papazoglu C, et al. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency. J Clin Invest. 134:e175199. https:\/\/doi.org\/10.1172\/JCI175199.","DOI":"10.1172\/JCI175199"},{"key":"7470_CR123","doi-asserted-by":"publisher","first-page":"20637","DOI":"10.1038\/s41598-021-00227-4","volume":"11","author":"X Yang","year":"2021","unstructured":"Yang X, Yu Q, Xu H, Zhou J. Upregulation of CD22 by Chidamide promotes car T cells functionality. Sci Rep. Nature Publishing Group; 2021;11:20637. https:\/\/doi.org\/10.1038\/s41598-021-00227-4.","journal-title":"Sci Rep"},{"key":"7470_CR124","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.omtn.2022.06.003","volume":"29","author":"BB Madison","year":"2022","unstructured":"Madison BB, Patil D, Richter M, Li X, Tong M, Cranert S, et al. Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells. Mol Ther Nucleic Acids. 2022;29:979\u201395. https:\/\/doi.org\/10.1016\/j.omtn.2022.06.003.","journal-title":"Mol Ther Nucleic Acids"},{"key":"7470_CR125","doi-asserted-by":"publisher","first-page":"e0267475","DOI":"10.1371\/journal.pone.0267475","volume":"17","author":"X Zhang","year":"2022","unstructured":"Zhang X, Ng YY, Du Z, Li Z, Chen C, Xiao L, et al. V\u03b39V\u03b42 T cells expressing a BCMA\u2014Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth. PLoS One. Public Library of Science; 2022;17:e0267475. https:\/\/doi.org\/10.1371\/journal.pone.0267475.","journal-title":"PLoS One"},{"key":"7470_CR126","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","volume":"29","author":"YY Ng","year":"2022","unstructured":"Ng YY, Du Z, Zhang X, Chng WJ, Wang S. CXCR4 and anti-BCMA car co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model. Cancer Gene Ther. 2022;29:475\u201383. https:\/\/doi.org\/10.1038\/s41417-021-00365-x.","journal-title":"Cancer Gene Ther"},{"key":"7470_CR127","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","volume":"35","author":"L Lin","year":"2021","unstructured":"Lin L, Cho S-F, Xing L, Wen K, Li Y, Yu T, et al. Preclinical evaluation of CD8+ anti-BCMA mRNA car T cells for treatment of multiple myeloma. Leukemia. Nature Publishing Group; 2021;35:752\u201363. https:\/\/doi.org\/10.1038\/s41375-020-0951-5.","journal-title":"Leukemia"},{"key":"7470_CR128","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJD, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. Nature Publishing Group; 2015;29:1637\u201347. https:\/\/doi.org\/10.1038\/leu.2015.52.","journal-title":"Leukemia"},{"key":"7470_CR129","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","volume":"30","author":"CF Magnani","year":"2023","unstructured":"Magnani CF, Myburgh R, Brunn S, Chambovey M, Ponzo M, Volta L, et al. Anti-CD117 car T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. Mol Ther Oncolytics. 2023;30:56\u201371. https:\/\/doi.org\/10.1016\/j.omto.2023.07.003.","journal-title":"Mol Ther Oncolytics"},{"key":"7470_CR130","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2217\/imt-2021-0143","volume":"14","author":"X Zhang","year":"2022","unstructured":"Zhang X, Ang WX, Du Z, Ng YY, Zha S, Chen C, et al. A CD123-specific chimeric antigen receptor augments anti-acute myeloid leukemia activity of V\u03b39V\u03b42 T cells. Immunotherapy. Taylor & Francis; 2022;14:321\u201336. https:\/\/doi.org\/10.2217\/imt-2021-0143.","journal-title":"Immunotherapy"},{"key":"7470_CR131","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","volume":"20","author":"W-H Lee","year":"2021","unstructured":"Lee W-H, Ye Z, Cheung AMS, Goh YPS, Oh HLJ, Rajarethinam R, et al. Effective killing of acute myeloid leukemia by TIM-3 targeted chimeric antigen receptor T cells. Mol Cancer Ther. 2021;20:1702\u201312. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0155.","journal-title":"Mol Cancer Ther"},{"key":"7470_CR132","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.3390\/ijms20112764","volume":"20","author":"DC Harrer","year":"2019","unstructured":"Harrer DC, Schuler G, D\u00f6rrie J, Schaft N. CSPG4-specific car T cells for high-risk childhood B cell precursor leukemia. Int J Mol Sci. Multidisciplinary Digital Publishing Institute; 2019;20:2764. https:\/\/doi.org\/10.3390\/ijms20112764.","journal-title":"Int J Mol Sci"},{"key":"7470_CR133","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.omto.2019.12.006","volume":"16","author":"YY Ng","year":"2020","unstructured":"Ng YY, Tay JCK, Wang S. CXCR1 expression to improve Anti-Cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts. Mol Ther - Oncolytics. Elsevier; 2020;16:75\u201385. https:\/\/doi.org\/10.1016\/j.omto.2019.12.006.","journal-title":"Mol Ther - Oncolytics"},{"key":"7470_CR134","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2217\/imt-2019-0137","volume":"12","author":"Z Li","year":"2020","unstructured":"Li Z, Chi Z, Ang W-X, Chen C, Tay JC, Ng Y-Y, et al. Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D rna car. Immunotherapy. Taylor & Francis; 2020;12:733\u201348. https:\/\/doi.org\/10.2217\/imt-2019-0137.","journal-title":"Immunotherapy"},{"key":"7470_CR135","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.omto.2020.04.013","volume":"17","author":"WX Ang","year":"2020","unstructured":"Ang WX, Ng YY, Xiao L, Chen C, Li Z, Chi Z, et al. Electroporation of NKG2D rna car improves V\u03b39V\u03b42 T cell responses against human solid tumor xenografts. Mol Ther - Oncolytics. Elsevier; 2020;17:421\u201330. https:\/\/doi.org\/10.1016\/j.omto.2020.04.013.","journal-title":"Mol Ther - Oncolytics"},{"key":"7470_CR136","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.3390\/cancers14205033","volume":"14","author":"DC Harrer","year":"2022","unstructured":"Harrer DC, Schenkel C, Berking C, Herr W, Abken H, D\u00f6rrie J, et al. Decitabine-mediated Upregulation of CSPG4 in ovarian carcinoma cells enables targeting by CSPG4-specific CAR-T cells. Cancers. Multidisciplinary Digital Publishing Institute; 2022;14:5033. https:\/\/doi.org\/10.3390\/cancers14205033.","journal-title":"Cancers"},{"key":"7470_CR137","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/cancers11050696","volume":"11","author":"B Simon","year":"2019","unstructured":"Simon B, Harrer DC, Schuler-Thurner B, Schuler G, Uslu U. Arming T cells with a gp100-specific TCR and a CSPG4-specific car using combined DNA- and RNA-Based receptor transfer. Cancers. Multidisciplinary Digital Publishing Institute; 2019;11:696. https:\/\/doi.org\/10.3390\/cancers11050696.","journal-title":"Cancers"},{"key":"7470_CR138","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3390\/cancers11081198","volume":"11","author":"M Wiesinger","year":"2019","unstructured":"Wiesinger M, M\u00e4rz J, Kummer M, Schuler G, D\u00f6rrie J, Schuler-Thurner B, et al. Clinical-scale production of CAR-T cells for the treatment of melanoma patients by mRNA transfection of a CSPG4-specific car under full GMP compliance. Cancers. Multidisciplinary Digital Publishing Institute; 2019;11:1198. https:\/\/doi.org\/10.3390\/cancers11081198.","journal-title":"Cancers"},{"key":"7470_CR139","doi-asserted-by":"publisher","first-page":"e004450","DOI":"10.1136\/jitc-2021-004450","volume":"10","author":"JB Foster","year":"2022","unstructured":"Foster JB, Griffin C, Rokita JL, Stern A, Brimley C, Rathi K, et al. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. J Immunother Cancer. BMJ Specialist Journals; 2022;10:e004450. https:\/\/doi.org\/10.1136\/jitc-2021-004450.","journal-title":"J Immunother Cancer"},{"key":"7470_CR140","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/cancers12102735","volume":"12","author":"K Fujiwara","year":"2020","unstructured":"Fujiwara K, Sasawatari S, Nakai S, Imaeda K, Nagai S, Matsuno Y, et al. Predicting the efficacy and safety of TACTICs (tumor angiogenesis-specific CAR-T cells impacting cancers) therapy for soft tissue sarcoma patients. Cancers. Multidisciplinary Digital Publishing Institute; 2020;12:2735. https:\/\/doi.org\/10.3390\/cancers12102735.","journal-title":"Cancers"},{"key":"7470_CR141","doi-asserted-by":"publisher","unstructured":"Ohtani Y, Ross K, Dandekar A, Gabbasov R, Klichinsky M. Development of an M1-polarized, non-viral chimeric antigen receptor macrophage (CAR-M) platform for cancer immunotherapy. J Immunother Cancer [internet]. BMJ Specialist Journals; 128; 2020 [cited 2025 Jan 17];8. https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0128.","DOI":"10.1136\/jitc-2020-SITC2020.0128"},{"key":"7470_CR142","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12967-018-1394-x","volume":"16","author":"J Proff","year":"2018","unstructured":"Proff J, Brey CU, Ensser A, Holter W, Lehner M. Turning the tables on cytomegalovirus: targeting viral fc receptors by CARs containing mutated CH2\u2013CH3 IgG spacer domains. J Transl Med. 2018;16:26. https:\/\/doi.org\/10.1186\/s12967-018-1394-x.","journal-title":"J Transl Med"},{"key":"7470_CR143","doi-asserted-by":"publisher","first-page":"2400024","DOI":"10.1002\/advs.202400024","volume":"11","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Li H, Lu Q, Zhang Z, Li J, Wang Z, et al. mRNA-Engineered CD5-CAR-\u03b3\u03b4TCD5- cells for the immunotherapy of T-Cell acute lymphoblastic leukemia. Adv Sci (Weinh). 2024;11:2400024. https:\/\/doi.org\/10.1002\/advs.202400024.","journal-title":"Adv Sci (Weinh)"},{"key":"7470_CR144","doi-asserted-by":"publisher","first-page":"e70140","DOI":"10.1002\/ctm2.70140","volume":"15","author":"PY Lam","year":"2025","unstructured":"Lam PY, Omer N, Wong JKM, Tu C, Alim L, Rossi GR, et al. Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted car. Clin Transl Med. 2025;15:e70140. https:\/\/doi.org\/10.1002\/ctm2.70140.","journal-title":"Clin Transl Med"},{"key":"7470_CR145","doi-asserted-by":"publisher","first-page":"2147317","DOI":"10.1080\/2162402X.2022.2147317","volume":"12","author":"CA Di Trani","year":"2023","unstructured":"Di Trani CA, Cirella A, Arrizabalaga L, \u00c1 B, Fernandez-Sendin M, Russo-Cabrera JS, et al. Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8+ T cells eradicates peritoneal metastases in mouse models. OncoImmunology. Taylor & Francis; 2023;12:2147317. https:\/\/doi.org\/10.1080\/2162402X.2022.2147317.","journal-title":"OncoImmunology"},{"key":"7470_CR146","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.30.605730","author":"K Gu","year":"2024","unstructured":"Gu K, Liang T, Hu L, Zhao Y, Ying W, Zhang M, et al. Intraperitoneal programming of tailored car macrophages via mRNA-LNP to boost cancer immunotherapy [internet]. Bioengineering. 2024. https:\/\/doi.org\/10.1101\/2024.07.30.605730. cited 2025 Feb 9.","journal-title":"Bioengineering"},{"key":"7470_CR147","doi-asserted-by":"publisher","DOI":"10.1101\/2024.11.06.621821","author":"S Zhang","year":"2024","unstructured":"Zhang S, Lu H, Zhang H, Ding X, Wu Q, Lei A, et al. In vivo engineered quadrivalent CAR-macrophages break tumor barrier, remodel TME and overcome tumor heterogeneity through antigen spreading [internet]. Bioengineering. 2024. https:\/\/doi.org\/10.1101\/2024.11.06.621821. cited 2025 Feb 9.","journal-title":"Bioengineering"},{"key":"7470_CR148","doi-asserted-by":"publisher","first-page":"e009726","DOI":"10.1136\/jitc-2024-009726","volume":"12","author":"W Luo","year":"2024","unstructured":"Luo W, Hoang H, Zhu H, Miller K, Mo X, Eguchi S, et al. Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy. J Immunother Cancer. BMJ Specialist Journals; 2024;12:e009726. https:\/\/doi.org\/10.1136\/jitc-2024-009726.","journal-title":"J Immunother Cancer"},{"key":"7470_CR149","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M, Miljkovi\u0107 MD, Chahin N, Sahagian G, et al. Safety and efficacy of autologous rna chimeric antigen receptor T-cell (rCAR-T) therapy in Myasthenia Gravis: a prospective, multicenter, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 2023;22:578\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(23)00194-1.","journal-title":"Lancet Neurol"},{"key":"7470_CR150","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1:26\u201331. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0006.","journal-title":"Cancer Immunol Res"},{"key":"7470_CR151","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty GL, O\u2019Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, et al. Activity of Mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. Elsevier; 2018;155:29\u201332. https:\/\/doi.org\/10.1053\/j.gastro.2018.03.029.","journal-title":"Gastroenterology"},{"key":"7470_CR152","doi-asserted-by":"publisher","unstructured":"Argueta S, Melber FK, Gorgievski M, D\u2019Alessandro J, Cochran E, Grudzien-Nogalska E, et al. Preclinical development of MT-303, a novel LNP-formulated GPC3-specific car mRNA, for in vivo programming of monocytes to treat hepatocellular carcinoma. J Immunother Cancer [internet]. BMJ Publishing Group Ltd; 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.1125. cited 2025 Oct 27.","DOI":"10.1136\/jitc-2024-SITC2024.1125"},{"key":"7470_CR153","unstructured":"Lemech CR, Cosman R, Humphries TG, Kichenadasse G, Richardson GE, Nagrial A, et al. First-in-human mRNA car therapy: correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors."},{"key":"7470_CR154","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","volume":"587","author":"NC Henderson","year":"2020","unstructured":"Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020;587:555\u201366. https:\/\/doi.org\/10.1038\/s41586-020-2938-9.","journal-title":"Nature"},{"key":"7470_CR155","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, et al. Targeting cardiac fibrosis with engineered T cells. Nature. 2019;573:430\u201333. https:\/\/doi.org\/10.1038\/s41586-019-1546-z.","journal-title":"Nature"},{"key":"7470_CR156","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41421-024-00718-4","volume":"10","author":"Z Gao","year":"2024","unstructured":"Gao Z, Yan L, Meng J, Lu Z, Ge K, Jiang Z, et al. Targeting cardiac fibrosis with chimeric antigen receptor macrophages. Cell Discov. 2024;10:86. https:\/\/doi.org\/10.1038\/s41421-024-00718-4.","journal-title":"Cell Discov"},{"key":"7470_CR157","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1161\/CIRCRESAHA.124.325212","volume":"135","author":"J Wang","year":"2024","unstructured":"Wang J, Du H, Xie W, Bi J, Zhang H, Liu X, et al. CAR-Macrophage therapy alleviates myocardial ischemia-reperfusion injury. Circ Res. 2024;135:1161\u201374. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.325212.","journal-title":"Circ Res"},{"key":"7470_CR158","doi-asserted-by":"publisher","first-page":"ra9573","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and Can establish Memory in patients with advanced leukemia. Sci Transl Med American Association for the Advancement of Science; 2011;3:ra9573\u20139573. https:\/\/doi.org\/10.1126\/scitranslmed.3002842.","journal-title":"Sci Transl Med"},{"key":"7470_CR159","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.coi.2011.03.003","volume":"23","author":"G Soldevila","year":"2011","unstructured":"Soldevila G, Raman C, Lozano F. The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease. Curr Opin Immunol. 2011;23:310\u201318. https:\/\/doi.org\/10.1016\/j.coi.2011.03.003.","journal-title":"Curr Opin Immunol"},{"key":"7470_CR160","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1084\/jem.152.1.229","volume":"152","author":"An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells","year":"1980","unstructured":"An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells. J Exp Med. 1980;152:229\u201334.","journal-title":"J Exp Med"},{"key":"7470_CR161","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev-pathol-011110-130327","volume":"6","author":"DJ Stearns-Kurosawa","year":"2011","unstructured":"Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG. The pathogenesis of sepsis. Annu Rev Pathol. 2011;6:19\u201348. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130327.","journal-title":"Annu Rev Pathol"},{"key":"7470_CR162","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40779-022-00422-y","volume":"9","author":"D Liu","year":"2022","unstructured":"Liu D, Huang S-Y, Sun J-H, Zhang H-C, Cai Q-L, Gao C, et al. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Mil Med Res. 2022;9:56. https:\/\/doi.org\/10.1186\/s40779-022-00422-y.","journal-title":"Mil Med Res"},{"key":"7470_CR163","doi-asserted-by":"publisher","first-page":"103604","DOI":"10.1016\/j.sjbs.2023.103604","volume":"30","author":"B Ali Alghamdi","year":"2023","unstructured":"Ali Alghamdi B, I A-J, Jm A-S, Musamed Alshamrani H, Bg A-O, Almazmomi K, et al. Antimicrobial resistance in methicillin-resistant staphylococcus aureus. Saudi J Biol Sci. 2023;30:103604. https:\/\/doi.org\/10.1016\/j.sjbs.2023.103604.","journal-title":"Saudi J Biol Sci"},{"key":"7470_CR164","doi-asserted-by":"publisher","first-page":"7687","DOI":"10.1073\/pnas.122108599","volume":"99","author":"MC Enright","year":"2002","unstructured":"Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A. 2002;99:7687\u201392. https:\/\/doi.org\/10.1073\/pnas.122108599.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7470_CR165","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrmicro3521","volume":"13","author":"V Thammavongsa","year":"2015","unstructured":"Thammavongsa V, Kim HK, Missiakas D, Schneewind O. Staphylococcal manipulation of host immune responses. Nat Rev Microbiol. 2015;13:529\u201343. https:\/\/doi.org\/10.1038\/nrmicro3521.","journal-title":"Nat Rev Microbiol"},{"key":"7470_CR166","doi-asserted-by":"publisher","unstructured":"Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. Nature Publishing Group; 2025;1\u201312. https:\/\/doi.org\/10.1038\/s41591-025-03495-z.","DOI":"10.1038\/s41591-025-03495-z"},{"key":"7470_CR167","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 car T cells for patients with solid cancers. Nature. Nature Publishing Group; 2025;637:940\u201346. https:\/\/doi.org\/10.1038\/s41586-024-08261-8.","journal-title":"Nature"},{"key":"7470_CR168","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted car T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11:2748\u201363. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0407.","journal-title":"Cancer Discov"},{"key":"7470_CR169","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1073\/pnas.1312789111","volume":"111","author":"PR Kumaresan","year":"2014","unstructured":"Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A. 2014;111:10660\u201365. https:\/\/doi.org\/10.1073\/pnas.1312789111.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7470_CR170","doi-asserted-by":"publisher","first-page":"eabh1209","DOI":"10.1126\/scitranslmed.abh1209","volume":"14","author":"M Seif","year":"2022","unstructured":"Seif M, Kakoschke TK, Ebel F, Bellet MM, Trinks N, Renga G, et al. Car T cells targeting aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models. Sci Transl Med. American Association for the Advancement of Science; 2022;14:eabh1209. https:\/\/doi.org\/10.1126\/scitranslmed.abh1209.","journal-title":"Sci Transl Med"},{"key":"7470_CR171","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s42255-022-00537-5","volume":"4","author":"H Aghajanian","year":"2022","unstructured":"Aghajanian H, Rurik JG, Epstein JA. CAR-based therapies: opportunities for immuno-medicine beyond cancer. Nat Metab. 2022;4:163\u201369. https:\/\/doi.org\/10.1038\/s42255-022-00537-5.","journal-title":"Nat Metab"},{"key":"7470_CR172","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s42255-021-00483-8","volume":"3","author":"CD Wiley","year":"2021","unstructured":"Wiley CD, Campisi J. The metabolic roots of senescence: mechanisms and opportunities for intervention. Nat Metab. Nature Publishing Group; 2021;3:1290\u2013301. https:\/\/doi.org\/10.1038\/s42255-021-00483-8.","journal-title":"Nat Metab"},{"key":"7470_CR173","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","volume":"47","author":"LJ Hickson","year":"2019","unstructured":"Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446\u201356. https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.069.","journal-title":"EBioMedicine"},{"key":"7470_CR174","doi-asserted-by":"publisher","first-page":"111591","DOI":"10.1016\/j.mad.2021.111591","volume":"200","author":"EOW Gerdes","year":"2021","unstructured":"Gerdes EOW, Misra A, Netto JME, Tchkonia T, Kirkland JL. Strategies for late phase preclinical and early clinical trials of senolytics. Mech Ageing Dev. 2021;200:111591. https:\/\/doi.org\/10.1016\/j.mad.2021.111591.","journal-title":"Mech Ageing Dev"},{"key":"7470_CR175","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.tcb.2020.07.002","volume":"30","author":"M Borghesan","year":"2020","unstructured":"Borghesan M, Hoogaars WMH, Varela-Eirin M, Talma N, Demaria M. A senescence-centric view of aging: implications for longevity and disease. Trends Cell Biol. Elsevier; 2020;30:777\u201391. https:\/\/doi.org\/10.1016\/j.tcb.2020.07.002.","journal-title":"Trends Cell Biol"},{"key":"7470_CR176","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor C, Feucht J, Leibold J, Ho Y-J, Zhu C, Alonso-Curbelo D, et al. Senolytic car T cells reverse senescence-associated pathologies. Nature. 2020;583:127\u201332. https:\/\/doi.org\/10.1038\/s41586-020-2403-9.","journal-title":"Nature"},{"key":"7470_CR177","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","volume":"9","author":"A Titov","year":"2018","unstructured":"Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O, et al. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death Dis. 2018;9:897. https:\/\/doi.org\/10.1038\/s41419-018-0918-x.","journal-title":"Cell Death Dis"},{"key":"7470_CR178","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol. 2024;24:830\u201345. https:\/\/doi.org\/10.1038\/s41577-024-01035-3.","journal-title":"Nat Rev Immunol"},{"key":"7470_CR179","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted car T cells in refractory systemic lupus erythematosus. N Engl J Med. Massachusetts Medical Society; 2021;385:567\u201369. https:\/\/doi.org\/10.1056\/NEJMc2107725.","journal-title":"N Engl J Med"},{"key":"7470_CR180","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/annrheumdis-2023-eular.4161","volume":"82","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He S, Zhang W, Zhang H, Destefano V, Wada M, et al. OS1134\u2005NOVEL approach to treat systemic lupus erythematosus, by targetingthe \u201croot cause\u201d, B cells and plasma cells, using BCMA-CD19 compound car. Ann Rheumatic Dis. 2023;82:895. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.4161.","journal-title":"Ann Rheumatic Dis"},{"key":"7470_CR181","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller F, Boeltz S, Knitza J, Aigner M, V\u00f6lkl S, Kharboutli S, et al. CD19-targeted car T cells in refractory antisynthetase syndrome. Lancet. Elsevier; 2023;401:815\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(23)00023-5.","journal-title":"Lancet"},{"key":"7470_CR182","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"A-C Pecher","year":"2023","unstructured":"Pecher A-C, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-targeting car T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. Jama. 2023;329:2154\u201362. https:\/\/doi.org\/10.1001\/jama.2023.8753.","journal-title":"Jama"},{"key":"7470_CR183","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann C, M\u00fcller F, Distler JHW, Gy\u00f6rfi A-H, V\u00f6lkl S, Aigner M, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted car T cells. Ann Rheumatic Dis. BMJ Publishing Group Ltd; 2023;82:1117\u201320. https:\/\/doi.org\/10.1136\/ard-2023-223952.","journal-title":"Ann Rheumatic Dis"},{"key":"7470_CR184","doi-asserted-by":"publisher","first-page":"10335","DOI":"10.1182\/blood-2022-169265","volume":"140","author":"J Feng","year":"2022","unstructured":"Feng J, Hu Y, Zhang M, Cao H, Ke Y, Xu H, et al. Safety and efficacy of CD19 CAR-T cells for refractory systemic sclerosis: a phase I clinical trial. Blood. 2022;140:10335\u201336. https:\/\/doi.org\/10.1182\/blood-2022-169265.","journal-title":"Blood"},{"key":"7470_CR185","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt W, Freitag M, Claus M, Kolb P, Falcone V, R\u00f6hrich M, et al. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheumatic Dis. Elsevier; 2024;83:543\u201346. https:\/\/doi.org\/10.1136\/ard-2023-225174.","journal-title":"Ann Rheumatic Dis"},{"key":"7470_CR186","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, B\u00f6ttcher M, Desel C, Borie D, et al. Anti-CD19 car T cells for refractory myasthenia gravis. Lancet Neurol. Elsevier; 2023;22:1104\u201305. https:\/\/doi.org\/10.1016\/S1474-4422(23)00375-7.","journal-title":"Lancet Neurol"},{"key":"7470_CR187","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. Elsevier; 2024;5:550\u20138.e2. https:\/\/doi.org\/10.1016\/j.medj.2024.03.002.","journal-title":"Med"},{"key":"7470_CR188","doi-asserted-by":"publisher","unstructured":"Obarorakpor N, Patel D, Boyarov R, Amarsaikhan N, Cepeda JR, Eastes D, et al. Regulatory T cells targeting a pathogenic MHC class ii: insulin peptide epitope postpone spontaneous autoimmune diabetes. Front Immunol [Internet]. Frontiers; 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1207108. cited 2025 Feb 13.","DOI":"10.3389\/fimmu.2023.1207108"},{"key":"7470_CR189","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168601","author":"JA Spanier","year":"2023","unstructured":"Spanier JA, Fung V, Wardell CM, Alkhatib MH, Chen Y, Swanson LA, et al. Insulin B peptide-MHC class II-specific chimeric antigen receptor-tregs prevent autoimmune diabetes in mice. J Clin Investigation [internet]. 2023. https:\/\/doi.org\/10.1172\/JCI168601. cited 2025 Feb 13.","journal-title":"J Clin Investigation [internet]"},{"key":"7470_CR190","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/ajt.14175","volume":"17","author":"F Noyan","year":"2017","unstructured":"Noyan F, Zimmermann K, Hardtke-Wolenski M, Knoefel A, Schulde E, Geffers R, et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-Specific chimeric antigen receptor. Am J Transplant. 2017;17:917\u201330. https:\/\/doi.org\/10.1111\/ajt.14175.","journal-title":"Am J Transplant"},{"key":"7470_CR191","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI82771","volume":"126","author":"KG MacDonald","year":"2016","unstructured":"MacDonald KG, Hoeppli RE, Huang Q, Gillies J, Luciani DS, Orban PC, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. American Society for Clinical Investigation; 2016;126:1413\u201324. https:\/\/doi.org\/10.1172\/JCI82771.","journal-title":"J Clin Invest"},{"key":"7470_CR192","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","volume":"20","author":"C Raffin","year":"2020","unstructured":"Raffin C, Vo LT, Bluestone JA. Treg cell-based therapies: challenges and perspectives. Nat Rev Immunol. Nature Publishing Group; 2020;20:158\u201372. https:\/\/doi.org\/10.1038\/s41577-019-0232-6.","journal-title":"Nat Rev Immunol"},{"key":"7470_CR193","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. Elsevier; 2008;133:775\u201387. https:\/\/doi.org\/10.1016\/j.cell.2008.05.009.","journal-title":"Cell"},{"key":"7470_CR194","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ni.1774","volume":"10","author":"X Zhou","year":"2009","unstructured":"Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Mart\u00ednez-Llordella M, Ashby M, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009;10:1000\u201307. https:\/\/doi.org\/10.1038\/ni.1774.","journal-title":"Nat Immunol"},{"key":"7470_CR195","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/cmi.2015.12","volume":"12","author":"J Guo","year":"2015","unstructured":"Guo J, Zhou X. Regulatory T cells turn pathogenic. Cell Mol Immunol. Nature Publishing Group; 2015;12:525\u201332. https:\/\/doi.org\/10.1038\/cmi.2015.12.","journal-title":"Cell Mol Immunol"},{"key":"7470_CR196","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/cmi.2015.10","volume":"12","author":"Z Li","year":"2015","unstructured":"Li Z, Li D, Tsun A, Li B. FOXP3+ regulatory T cells and their functional regulation. Cell Mol Immunol. Nature Publishing Group; 2015;12:558\u201365. https:\/\/doi.org\/10.1038\/cmi.2015.10.","journal-title":"Cell Mol Immunol"},{"key":"7470_CR197","doi-asserted-by":"publisher","first-page":"15040","DOI":"10.1038\/celldisc.2015.40","volume":"1","author":"Y Bai","year":"2015","unstructured":"Bai Y, Kan S, Zhou S, Wang Y, Xu J, Cooke JP, et al. Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA. Cell Discov. 2015;1:15040. https:\/\/doi.org\/10.1038\/celldisc.2015.40.","journal-title":"Cell Discov"},{"key":"7470_CR198","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.ymthe.2023.07.015","volume":"31","author":"MD Tennant","year":"2023","unstructured":"Tennant MD, New C, Ferreira LMR, O\u2019Neil RT. Efficient T cell adoptive transfer in lymphoreplete hosts mediated by transient activation of Stat5 signaling. Mol Ther. 2023;31:2591\u201399. https:\/\/doi.org\/10.1016\/j.ymthe.2023.07.015.","journal-title":"Mol Ther"},{"key":"7470_CR199","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","volume":"38","author":"T Lei","year":"2024","unstructured":"Lei T, Wang Y, Zhang Y, Yang Y, Cao J, Huang J, et al. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of car T-cell therapy. Leukemia. 2024;38:2517\u201343. https:\/\/doi.org\/10.1038\/s41375-024-02444-y.","journal-title":"Leukemia"},{"key":"7470_CR200","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal car T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23:2255\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1300.","journal-title":"Clin Cancer Res"},{"key":"7470_CR201","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s12967-021-03146-0","volume":"19","author":"K Alishah","year":"2021","unstructured":"Alishah K, Birtel M, Masoumi E, Jafarzadeh L, Mirzaee HR, Hadjati J, et al. CRISPR\/Cas9-mediated TGF\u03b2RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. J Transl Med. 2021;19:482. https:\/\/doi.org\/10.1186\/s12967-021-03146-0.","journal-title":"J Transl Med"},{"key":"7470_CR202","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41587-022-01639-x","volume":"41","author":"X Dai","year":"2023","unstructured":"Dai X, Park JJ, Du Y, Na Z, Lam SZ, Chow RD, et al. Massively parallel knock-in engineering of human T cells. Nat Biotechnol. Nature Publishing Group; 2023;41:1239\u201355. https:\/\/doi.org\/10.1038\/s41587-022-01639-x.","journal-title":"Nat Biotechnol"},{"key":"7470_CR203","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","volume":"26","author":"C Georgiadis","year":"2018","unstructured":"Georgiadis C, Preece R, Nickolay L, Etuk A, Petrova A, Ladon D, et al. Long terminal repeat CRISPR-CAR-Coupled \u201cuniversal\u201d T cells mediate potent anti-leukemic effects. Mol Ther. 2018;26:1215\u201327. https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.025.","journal-title":"Mol Ther"},{"key":"7470_CR204","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, Van Der Stegen SJC, Hamieh M, Cunanan KM, et al. Targeting a car to the trac locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543:113\u201317. https:\/\/doi.org\/10.1038\/nature21405.","journal-title":"Nature"},{"key":"7470_CR205","doi-asserted-by":"publisher","first-page":"eadi1145","DOI":"10.1126\/scitranslmed.adi1145","volume":"15","author":"N Wellhausen","year":"2023","unstructured":"Wellhausen N, O\u2019Connell RP, Lesch S, Engel NW, Rennels AK, Gonzales D, et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci Transl Med. American Association for the Advancement of Science; 2023;15:eadi1145. https:\/\/doi.org\/10.1126\/scitranslmed.adi1145.","journal-title":"Sci Transl Med"},{"key":"7470_CR206","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 2023;56:2388\u2013407.e9. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.001.","journal-title":"Immunity"},{"key":"7470_CR207","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18:2188\u201398. https:\/\/doi.org\/10.1038\/s41423-021-00749-x.","journal-title":"Cell Mol Immunol"},{"key":"7470_CR208","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","volume":"15","author":"I Andreu-Saumell","year":"2024","unstructured":"Andreu-Saumell I, Rodriguez-Garcia A, M\u00fchlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsagu\u00e9 J, et al. Car affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition. Nat Commun. 2024;15:3552. https:\/\/doi.org\/10.1038\/s41467-024-47799-z.","journal-title":"Nat Commun"},{"key":"7470_CR209","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02282-4","author":"L Peng","year":"2024","unstructured":"Peng L, Renauer PA, Sferruzza G, Yang L, Zou Y, Fang Z, et al. In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat Biotechnol. 2024. https:\/\/doi.org\/10.1038\/s41587-024-02282-4.","journal-title":"Nat Biotechnol"},{"key":"7470_CR210","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41375-022-01572-7","volume":"36","author":"MJ Cox","year":"2022","unstructured":"Cox MJ, Manriquez Roman C, Tapper EE, Siegler EL, Chappell D, Durrant C, et al. GM-CSF disruption in cart cells modulates T cell activation and enhances cart cell anti-tumor activity. Leukemia. 2022;36:1635\u201345. https:\/\/doi.org\/10.1038\/s41375-022-01572-7.","journal-title":"Leukemia"},{"key":"7470_CR211","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133:697\u2013709. https:\/\/doi.org\/10.1182\/blood-2018-10-881722.","journal-title":"Blood"},{"key":"7470_CR212","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","volume":"25","author":"DT MacLeod","year":"2017","unstructured":"MacLeod DT, Antony J, Martin AJ, Moser RJ, Hekele A, Wetzel KJ, et al. Integration of a CD19 car into the TCR alpha chain locus streamlines production of allogeneic gene-edited car T cells. Mol Ther. Elsevier; 2017;25:949\u201361. https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.005.","journal-title":"Mol Ther"},{"key":"7470_CR213","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","volume":"25","author":"M Hale","year":"2017","unstructured":"Hale M, Mesojednik T, Romano Ibarra GS, Sahni J, Bernard A, Sommer K, et al. Engineering HIV-Resistant, Anti-HIV chimeric antigen receptor T cells. Mol Ther. 2017;25:570\u201379. https:\/\/doi.org\/10.1016\/j.ymthe.2016.12.023.","journal-title":"Mol Ther"},{"key":"7470_CR214","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","volume":"28","author":"S Prommersberger","year":"2021","unstructured":"Prommersberger S, Reiser M, Beckmann J, Danhof S, Amberger M, Quade-Lyssy P, et al. Caramba: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free sleeping beauty gene transfer to treat multiple myeloma. Gene Ther. 2021;28:560\u201371. https:\/\/doi.org\/10.1038\/s41434-021-00254-w.","journal-title":"Gene Ther"},{"key":"7470_CR215","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/cancers12051075","volume":"12","author":"S Kailayangiri","year":"2020","unstructured":"Kailayangiri S, Altvater B, Wiebel M, Jamitzky S, Rossig C. Overcoming heterogeneity of antigen expression for effective car T cell targeting of cancers. Cancers. 2020;12:1075. https:\/\/doi.org\/10.3390\/cancers12051075.","journal-title":"Cancers"},{"key":"7470_CR216","doi-asserted-by":"publisher","first-page":"2009489","DOI":"10.1002\/adfm.202009489","volume":"31","author":"R Fu","year":"2021","unstructured":"Fu R, Li H, Li R, McGrath K, Dotti G, Gu Z. Delivery techniques for enhancing car T cell therapy against solid tumors. Adv Funct Mater. 2021;31:2009489. https:\/\/doi.org\/10.1002\/adfm.202009489.","journal-title":"Adv Funct Mater"},{"key":"7470_CR217","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, et al. GD2-specific car T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther. 2016;24:1135\u201349. https:\/\/doi.org\/10.1038\/mt.2016.63.","journal-title":"Mol Ther"},{"key":"7470_CR218","doi-asserted-by":"publisher","unstructured":"F K, G Y, D H, W Y, L X, J H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer. Sci China Life Sci. 2016;59. https:\/\/doi.org\/10.1007\/s11427-016-5023-8. cited 2025 Mar 20.","DOI":"10.1007\/s11427-016-5023-8"},{"key":"7470_CR219","doi-asserted-by":"publisher","unstructured":"Dm O, Mp N, D A, Jj M, M K, Jjd M, et al. A single dose of peripherally infused EGFRvIII-directed car T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984. cited 2025 Mar 20.","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"7470_CR220","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, Dobrin A, Cabriolu A, Van Der Stegen SJC, Giavridis T, Mansilla-Soto J, et al. Car T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568:112\u201316. https:\/\/doi.org\/10.1038\/s41586-019-1054-1.","journal-title":"Nature"},{"key":"7470_CR221","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.14101","volume":"112","author":"A Mishra","year":"2024","unstructured":"Mishra A, Maiti R, Mohan P, Gupta P. Antigen loss following CAR-T cell therapy: mechanisms, implications, and potential solutions. Eur J Haematol. 2024;112:211\u201322. https:\/\/doi.org\/10.1111\/ejh.14101.","journal-title":"Eur J Haematol"},{"key":"7470_CR222","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1200\/JCO.2019.37.15_suppl.2523","volume":"37","author":"HA Burris","year":"2019","unstructured":"Burris HA, Patel MR, Cho DC, Clarke JM, Gutierrez M, Zaks TZ, et al. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. JCO. Wolters Kluwer; 2019;37:2523\u20132523. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2523.","journal-title":"JCO"},{"key":"7470_CR223","doi-asserted-by":"publisher","first-page":"CT301","DOI":"10.1158\/1538-7445.AM2020-CT301","volume":"80","author":"JS Lopez","year":"2020","unstructured":"Lopez JS, Camidge R, Iafolla M, Rottey S, Schuler M, Hellmann M, et al. Abstract CT301: a phase Ib study to evaluate RO7198457, an individualized neoantigen specific immunoTherapy (iNest), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cancer Res. 2020;80:CT301. https:\/\/doi.org\/10.1158\/1538-7445.AM2020-CT301.","journal-title":"Cancer Res"},{"key":"7470_CR224","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, L\u00f6wer M, et al. Personalized rna mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. Nature Publishing Group; 2017;547:222\u201326. https:\/\/doi.org\/10.1038\/nature23003.","journal-title":"Nature"},{"key":"7470_CR225","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. Nature Publishing Group; 2021;18:215\u201329. https:\/\/doi.org\/10.1038\/s41571-020-00460-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"24","key":"7470_CR226","doi-asserted-by":"publisher","first-page":"00270","DOI":"10.1016\/j.tips.2024.12.004","volume":"S0165-6147","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Lyu Z, Shen X, Fang Y, Yang L. Boosting CAR-T cell therapy through vaccine synergy. Trends Pharmacol Sci. 2025;S0165-6147(24):00270\u20130. https:\/\/doi.org\/10.1016\/j.tips.2024.12.004.","journal-title":"Trends Pharmacol Sci"},{"key":"7470_CR227","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, et al. An rna vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367:446\u201353. https:\/\/doi.org\/10.1126\/science.aay5967.","journal-title":"Science"},{"key":"7470_CR228","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, et al. Vaccine-boosted car T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186:3148\u201365.e20. https:\/\/doi.org\/10.1016\/j.cell.2023.06.002.","journal-title":"Cell"},{"key":"7470_CR229","doi-asserted-by":"publisher","unstructured":"Fu J, Wu S, Bao N, Wu L, Qu H, Wang Z, et al. A universal strategy of anti-tumor mRNA vaccine by harnessing \u201coff-the-shelf\u201d immunity. Adv Sci. n\/a:2401287. https:\/\/doi.org\/10.1002\/advs.202401287.","DOI":"10.1002\/advs.202401287"},{"key":"7470_CR230","doi-asserted-by":"publisher","first-page":"eadn9083","DOI":"10.1126\/science.adn9083","volume":"386","author":"E Ascic","year":"2024","unstructured":"Ascic E, \u00c5kerstr\u00f6m F, Sreekumar Nair M, Rosa A, Kurochkin I, Zimmermannova O, et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science. 2024;386:eadn9083. https:\/\/doi.org\/10.1126\/science.adn9083.","journal-title":"Science"},{"key":"7470_CR231","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-21-0502","volume":"13","author":"MH Linde","year":"2023","unstructured":"Linde MH, Fan AC, K\u00f6hnke T, Trotman-Grant AC, Gurev SF, Phan P, et al. Reprogramming cancer into antigen-presenting cells as a novel immunotherapy. Cancer Discov. 2023;13:1164\u201385. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0502.","journal-title":"Cancer Discov"},{"key":"7470_CR232","doi-asserted-by":"publisher","first-page":"eadd4817","DOI":"10.1126\/sciimmunol.add4817","volume":"8","author":"O Zimmermannova","year":"2023","unstructured":"Zimmermannova O, Ferreira AG, Ascic E, Velasco Santiago M, Kurochkin I, Hansen M, et al. Restoring tumor immunogenicity with dendritic cell reprogramming. Sci Immunol. 2023;8:eadd4817. https:\/\/doi.org\/10.1126\/sciimmunol.add4817.","journal-title":"Sci Immunol"},{"key":"7470_CR233","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.4155\/fmc-2020-0081","volume":"12","author":"AE Snook","year":"2020","unstructured":"Snook AE. Companion vaccines for car T-cell therapy: applying basic immunology to enhance therapeutic efficacy. Future Med Chem. Taylor & Francis; 2020;12:1359\u201362. https:\/\/doi.org\/10.4155\/fmc-2020-0081.","journal-title":"Future Med Chem"},{"key":"7470_CR234","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, et al. An rna vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. Nature Publishing Group; 2020;585:107\u201312. https:\/\/doi.org\/10.1038\/s41586-020-2537-9.","journal-title":"Nature"},{"key":"7470_CR235","doi-asserted-by":"publisher","first-page":"e2005191118","DOI":"10.1073\/pnas.2005191118","volume":"118","author":"H Zhang","year":"2021","unstructured":"Zhang H, You X, Wang X, Cui L, Wang Z, Xu F, et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc Natl Acad Sci. Proceedings of the National Academy of Sciences; 2021;118:e2005191118. https:\/\/doi.org\/10.1073\/pnas.2005191118.","journal-title":"Proc Natl Acad Sci"},{"key":"7470_CR236","doi-asserted-by":"publisher","first-page":"e2207841119","DOI":"10.1073\/pnas.2207841119","volume":"119","author":"J Chen","year":"2022","unstructured":"Chen J, Ye Z, Huang C, Qiu M, Song D, Li Y, et al. Lipid nanoparticle-mediated lymph node\u2013targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc Natl Acad Sci. Proceedings of the National Academy of Sciences; 2022;119:e2207841119. https:\/\/doi.org\/10.1073\/pnas.2207841119.","journal-title":"Proc Natl Acad Sci"},{"key":"7470_CR237","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2023.11.003","volume":"45","author":"S Pan","year":"2024","unstructured":"Pan S, Fan R, Han B, Tong A, Guo G. The potential of mRNA vaccines in cancer nanomedicine and immunotherapy. Trends Immunol. 2024;45:20\u201331. https:\/\/doi.org\/10.1016\/j.it.2023.11.003.","journal-title":"Trends Immunol"},{"key":"7470_CR238","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1038\/s41591-023-02623-x","volume":"29","author":"A Chehrazi-Raffle","year":"2023","unstructured":"Chehrazi-Raffle A, Budde LE, Pal SK. Boosting car T cells with anti-tumor mRNA vaccines. Nat Med. 2023;29:2711\u201312. https:\/\/doi.org\/10.1038\/s41591-023-02623-x.","journal-title":"Nat Med"},{"key":"7470_CR239","doi-asserted-by":"publisher","first-page":"13416","DOI":"10.3390\/ijms222413416","volume":"22","author":"H Qu","year":"2021","unstructured":"Qu H, Jin Q, Quan C. CLDN6: from traditional barrier function to emerging roles in cancers. Int J Mol Sci. 2021;22:13416. https:\/\/doi.org\/10.3390\/ijms222413416.","journal-title":"Int J Mol Sci"},{"key":"7470_CR240","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al. CLDN6-specific CAR-T cells plus amplifying rna vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. Nature Publishing Group; 2023;29:2844\u201353. https:\/\/doi.org\/10.1038\/s41591-023-02612-0.","journal-title":"Nat Med"},{"key":"7470_CR241","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nat Rev Clin Oncol. Nature Publishing Group; 2018;15:47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148.","journal-title":"Nat Rev Clin Oncol"},{"key":"7470_CR242","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in car T cell therapy. Nat Rev Clin Oncol. Nature Publishing Group; 2020;17:147\u201367. https:\/\/doi.org\/10.1038\/s41571-019-0297-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"7470_CR243","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herv\u00e9","year":"2019","unstructured":"Herv\u00e9 C, Laup\u00e8ze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how\u2019s and what\u2019s of vaccine reactogenicity. NPJ Vaccines. Nature Publishing Group; 2019;4:1\u201311. https:\/\/doi.org\/10.1038\/s41541-019-0132-6.","journal-title":"NPJ Vaccines"},{"key":"7470_CR244","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1126\/science.abq6990","volume":"378","author":"DJ Irvine","year":"2022","unstructured":"Irvine DJ, Maus MV, Mooney DJ, Wong WW. The future of engineered immune cell therapies. Science. 2022;378:853\u201358. https:\/\/doi.org\/10.1126\/science.abq6990.","journal-title":"Science"},{"key":"7470_CR245","unstructured":"Engineered cellular immunotherapies in cancer and beyond - PMC [internet]. 2025 Feb 14. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9305718IF: 50.0 Q1 B1\/. Accessed 14 Feb 2025."},{"key":"7470_CR246","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. Car immune cells: design principles, resistance and the next generation. Nature. 2023;614:635\u201348. https:\/\/doi.org\/10.1038\/s41586-023-05707-3.","journal-title":"Nature"},{"key":"7470_CR247","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","volume":"40","author":"G Walsh","year":"2022","unstructured":"Walsh G, Walsh E. Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022;40:1722\u201360. https:\/\/doi.org\/10.1038\/s41587-022-01582-x.","journal-title":"Nat Biotechnol"},{"key":"7470_CR248","unstructured":"Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system - PubMed [internet]. 2025 Feb 20. https:\/\/pubmed.ncbi.nlm.nih.gov\/39962245\/. Accessed 20 Feb 2025."},{"key":"7470_CR249","unstructured":"Intravenous administration of blood-brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system - PubMed [internet]. 2025 Feb 20. https:\/\/pubmed.ncbi.nlm.nih.gov\/39587229\/. Accessed 20 Feb 2025."},{"key":"7470_CR250","doi-asserted-by":"publisher","first-page":"e175015","DOI":"10.1172\/jci.insight.175015","volume":"9","author":"AB Kim","year":"2024","unstructured":"Kim AB, Xiao Q, Yan P, Pan Q, Pandey G, Grathwohl S, et al. Chimeric antigen receptor macrophages target and resorb amyloid plaques. JCI Insight. 2024;9:e175015. https:\/\/doi.org\/10.1172\/jci.insight.175015.","journal-title":"JCI Insight"},{"key":"7470_CR251","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/pharmaceutics17070803","volume":"17","author":"J Wang","year":"2025","unstructured":"Wang J, Chen R, Xie Y, Qin X, Zhou Y, Xu C. Endo\/lysosomal-escapable lipid nanoparticle platforms for enhancing mRNA delivery in cancer therapy. Pharmaceutics. Multidisciplinary Digital Publishing Institute; 2025;17:803. https:\/\/doi.org\/10.3390\/pharmaceutics17070803.","journal-title":"Pharmaceutics"},{"key":"7470_CR255","doi-asserted-by":"publisher","unstructured":"Rl B, Ka H, V J, B P, Ka W. Lipid nanoparticle formulations for enhanced Co-delivery of siRNA and mRNA. Nano Lett. 2018;18. https:\/\/doi.org\/10.1021\/acs.nanolett.8b01101. cited 2025 Feb 13.","DOI":"10.1021\/acs.nanolett.8b01101"},{"key":"7470_CR256","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","volume":"13","author":"S Li","year":"2022","unstructured":"Li S, Hu Y, Li A, Lin J, Hsieh K, Schneiderman Z, et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nat Commun. Nature Publishing Group; 2022;13:5561. https:\/\/doi.org\/10.1038\/s41467-022-33157-4.","journal-title":"Nat Commun"},{"key":"7470_CR257","doi-asserted-by":"publisher","first-page":"113900","DOI":"10.1016\/j.addr.2021.113900","volume":"176","author":"A-K Minnaert","year":"2021","unstructured":"Minnaert A-K, Vanluchene H, Verbeke R, Lentacker I, De Smedt SC, Raemdonck K, et al. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: getting the message across. Adv Drug Delivery Rev. 2021;176:113900. https:\/\/doi.org\/10.1016\/j.addr.2021.113900.","journal-title":"Adv Drug Delivery Rev"},{"key":"7470_CR259","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. Car T therapy beyond cancer: the evolution of a living drug. Nature. Nature Publishing Group; 2023;619:707\u201315. https:\/\/doi.org\/10.1038\/s41586-023-06243-w.","journal-title":"Nature"},{"key":"7470_CR260","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","volume":"372","author":"S Soroudi","year":"2024","unstructured":"Soroudi S, Jaafari MR, Arabi L. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and car T cell therapy. J Control Release. 2024;372:113\u201340. https:\/\/doi.org\/10.1016\/j.jconrel.2024.06.023.","journal-title":"J Control Release"},{"key":"7470_CR261","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","volume":"96","author":"L Zhang","year":"2019","unstructured":"Zhang L, Sosinowski T, Cox AR, Cepeda JR, Sekhar NS, Hartig SM, et al. Chimeric antigen receptor (car) T cells targeting a pathogenic MHC class II: peptide complex modulate the progression of autoimmune diabetes. J Autoimmunity. 2019;96:50\u201358. https:\/\/doi.org\/10.1016\/j.jaut.2018.08.004.","journal-title":"J Autoimmunity"},{"key":"7470_CR262","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41421-022-00433-y","volume":"8","author":"S Chen","year":"2022","unstructured":"Chen S, Chen G, Xu F, Sun B, Chen X, Hu W, et al. Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells. Cell Discov. 2022;8:80. https:\/\/doi.org\/10.1038\/s41421-022-00433-y.","journal-title":"Cell Discov"},{"key":"7470_CR263","unstructured":"Chimeric antigen receptor (car) T cells targeting a pathogenic MHC class II: peptide complex modulate the progression of autoimmune diabetes - PubMed [internet]. 2025 Feb 14. https:\/\/pubmed.ncbi.nlm.nih.gov\/30122420\/. Accessed 14 Feb 2025."},{"key":"7470_CR264","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-15-0163","volume":"4","author":"S Van Lint","year":"2016","unstructured":"Van Lint S, Renmans D, Broos K, Goethals L, Maenhout S, Benteyn D, et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by Cross-presenting dendritic cells. Cancer Immunol Res. 2016;4:146\u201356. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0163.","journal-title":"Cancer Immunol Res"},{"key":"7470_CR265","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1158\/0008-5472.CAN-18-2867","volume":"79","author":"OAW Haabeth","year":"2019","unstructured":"Haabeth OAW, Blake TR, McKinlay CJ, Tveita AA, Sallets A, Waymouth RM, et al. Local delivery of Ox40l, Cd80, and Cd86 mRNA kindles global anticancer immunity. Cancer Res. 2019;79:1624\u201334. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2867.","journal-title":"Cancer Res"},{"key":"7470_CR266","doi-asserted-by":"publisher","first-page":"17438","DOI":"10.1073\/pnas.1418516111","volume":"111","author":"J Ren","year":"2014","unstructured":"Ren J, Chen X, Chen ZJ. IKK\u03b2 is an IRF5 kinase that instigates inflammation. Proc Natl Acad Sci. 2014;111:17438\u201343. https:\/\/doi.org\/10.1073\/pnas.1418516111.","journal-title":"Proc Natl Acad Sci"},{"key":"7470_CR267","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/ni.1990","volume":"12","author":"T Krausgruber","year":"2011","unstructured":"Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol. 2011;12:231\u201338. https:\/\/doi.org\/10.1038\/ni.1990.","journal-title":"Nat Immunol"},{"key":"7470_CR268","doi-asserted-by":"publisher","first-page":"eaat9143","DOI":"10.1126\/scitranslmed.aat9143","volume":"11","author":"SL Hewitt","year":"2019","unstructured":"Hewitt SL, Bai A, Bailey D, Ichikawa K, Zielinski J, Karp R, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs. Sci Transl Med. American Association for the Advancement of Science; 2019;11:eaat9143. https:\/\/doi.org\/10.1126\/scitranslmed.aat9143.","journal-title":"Sci Transl Med"},{"key":"7470_CR269","doi-asserted-by":"publisher","first-page":"10100","DOI":"10.18632\/oncotarget.2463","volume":"5","author":"K Van der Jeught","year":"2014","unstructured":"Van der Jeught K, Joe PT, Bialkowski L, Heirman C, Daszkiewicz L, Liechtenstein T, et al. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-\u03b2 and the ectodomain of the TGF-\u03b2 receptor ii potentiates antitumor immunity. Oncotarget. Impact Journals; 2014;5:10100\u201313. https:\/\/doi.org\/10.18632\/oncotarget.2463.","journal-title":"Oncotarget"},{"key":"7470_CR270","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","volume":"26","author":"SL Hewitt","year":"2020","unstructured":"Hewitt SL, Bailey D, Zielinski J, Apte A, Musenge F, Karp R, et al. Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment. Clin Cancer Res. 2020;26:6284\u201398. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0472.","journal-title":"Clin Cancer Res"},{"key":"7470_CR271","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41467-022-28279-8","volume":"13","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Chen J, Zhou H, Zeng X, Ruan Z, Pu Z, et al. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nat Commun. 2022;13:758. https:\/\/doi.org\/10.1038\/s41467-022-28279-8.","journal-title":"Nat Commun"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07470-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07470-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07470-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:34:34Z","timestamp":1765542874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07470-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":267,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7470"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07470-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1393"}}